Lenz, Lauren
Neff, Chris
Solimeno, Cara
Cogan, Elizabeth S.
Abramson, Vandana G.
Boughey, Judy C.
Falkson, Carla
Goetz, Matthew P.
Ford, James M.
Gradishar, William J.
Jankowitz, Rachel C.
Kaklamani, Virginia G.
Marcom, P. Kelly
Richardson, Andrea L.
Storniolo, Anna Maria
Tung, Nadine M.
Vinayak, Shaveta
Hodgson, Darren R.
Lai, Zhongwu
Dearden, Simon
Hennessy, Bryan T.
Mayer, Erica L.
Mills, Gordon B.
Slavin, Thomas P.
Gutin, Alexander
Connolly, Roisin M.
Telli, Melinda L.
Stearns, Vered
Lanchbury, Jerry S.
Timms, Kirsten M. http://orcid.org/0000-0003-4923-2518
Funding for this research was provided by:
Myriad Genetics (Myriad Genetics)
Article History
Received: 1 June 2023
Accepted: 7 July 2023
First Online: 17 August 2023
Declarations
:
: The analysis described in this manuscript was performed using de-identified data obtained from previously Institutional Review Board–approved protocols. No protected health information is reported; only aggregate data are presented in the manuscript. Therefore, this analysis did not meet the U.S. Health and Human Services definition of research on human subjects (HHS 46.102) and did not require Institutional Review Board approval.
: Patient consent for this manuscript was not required given that this was a retrospective analysis of aggregate data.
: <b>Ms. Lenz</b>, <b>Mr. Neff</b>, <b>Ms. Solimeno</b>, <b>Dr. Cogan</b>, <b>Dr. Slavin</b>, <b>Dr. Gutin</b>, <b>Dr. Lanchbury</b> and <b>Dr. Timms</b> were all employed by Myriad Genetics at the time of this study and received salary and stock options. <b>Dr. Abramson</b> has received consulting fees from AstraZeneca, Eisai, Daiichi Sankyo, Macrogenics, and Seagen. <b>Dr. Boughey</b> has received research funding from Lilly and participated in a Data Safety Monitoring Board with Cairns Surgical. <b>Dr. Falkson</b> has received honoraria from Exact Sciences, Curio Sciences, Agendia, and Biotheranostics for advisory boards; has received honoraria from OncLive/MJH Life Sciences for Speaker’s Bureau activity; and has received research funding to institution from Oncolytics Biotech, Quantumleap Health, and Eli Lilly. <b>Dr. Goetz</b> has received personal fees for CME activities from Research to Practice and Clinical Education Alliance; has received consulting fees to the Mayo Clinic from AstraZeneca, Biovica, Biotheranostics, Blueprint Medicines, Eagles Pharmaceuticals, Lilly, Novartis, Pfizer, and Sermonix; and has received grant funding to the Mayo Clinic from Lilly, Pfizer, and Sermonix. <b>Dr. Ford</b> has received research funding from Pfizer, Genentech, Merus, PUMA, and AstraZeneca. <b>Dr. Kaklamani</b> has received speaker fees from Pfizer, Gilead, Genentech, Genomic Health, Puma, Eisai, Novartis, Daiichi Sankyo, and Seagen; has received consultant fees from Puma, AstraZeneca, Athenex, and Gilead; and has received research funding from Eisai. <b>Dr. Marcom</b> is employed by Veracyte, Inc. <b>Dr. Richardson</b> is an inventor on an IP owned by Partners Healthcare and licensed to Myriad Genetics. <b>Dr. Storniolo</b> has received consulting fees from AstraZeneca. <b>Dr. Tung</b> has received research funding from AstraZeneca and has consulted for GSK. <b>Dr. Hodgson</b>, <b>Dr. Lai</b>, and <b>Mr. Dearden</b> were employed by AstraZeneca at the time of the study and received salary and restricted stock shares. <b>Dr. Hennessy</b> has received research funding from Bayer, AstraZeneca, and Daiichi Sankyo and has received royalties from Myriad Genetics. <b>Dr. Mayer</b> has received consulting fees from Lilly, Novartis, AstraZeneca, and Gilead. <b>Dr. Mills</b> is on the scientific advisory board for Amphista, Astex, AstraZeneca, BlueDot, Chrysalis Biotechnology, Ellipses Pharma, ImmunoMet, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Quereator, Roche, SignalChem Lifesciences, Tarveda, Turbine, and Zentalis Pharmaceuticals; has stock options with BlueDot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, and Turbine; has licensed the HRD assay to Myriad Genetics and DSP patents to Nanostring; and has sponsored research support from AstraZeneca. <b>Dr. Connolly</b> has received research funding from Pfizer; has received research funding to institution for clinical trials from MSD Ireland, Pfizer, Daiichi Sankyo, and AstraZeneca; and has consulted for Seagen and AstraZeneca/Daiichi without renumeration. <b>Dr. Telli</b> reports research support (to her institution) from AbbVie, Arvinas, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GlaxoSmithKline, Hummingbird Biosciences, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro and Vertex and has received consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Blueprint Medicines, Celgene, Daiichi Sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, G1 Therapeutics, Guardant, Immunomedics, Lilly, Merck, Natera, Novartis, OncoSec, Pfizer, RefleXion and Sanofi. <b>Dr. Stearns</b> has received research grants (to his institution) from AbbVie, Biocept, Pfizer, Novartis, QUE Oncology, and Puma Biotechnology; is a member of the advisory board for Novartis; is the chair of the Data Safety Monitoring Board for AstraZeneca; and has received nonfinancial support from Foundation Medicine. All other authors have no disclosures to report.